Zobrazeno 1 - 10
of 15
pro vyhledávání: '"T. Lisitsyna"'
Publikováno v:
Annals of the Rheumatic Diseases. 81:43-44
BackgroundOlokizumab (OKZ) is an interleukin-6-inhibitor for treatment of Rheumatoid Arthritis (RA). In these analyses, we present patient reported outcomes (PROs) reported by MTX-IR patients with moderate to severely active RA treated with OKZ vs ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cce79b597db91f62285fd30cdd2b2b3f
https://doi.org/10.1136/annrheumdis-2022-eular.1977
https://doi.org/10.1136/annrheumdis-2022-eular.1977
Publikováno v:
Immunopathology, Allergology, Infectology. :17-24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44d0dd1e8cfc41652d64e2070a3f6c60
https://doi.org/10.14427/jipai.2019.3.17
https://doi.org/10.14427/jipai.2019.3.17
Autor:
A. Abramkin, T. Lisitsyna, D. Veltishchev, O. Seravina, O. Kovalevskaya, S. Glukhova, E. Nasonov
Publikováno v:
Annals of the Rheumatic Diseases. 81:1713.1-1714
BackgroundAnxiety and depressive disorders (ADD) significantly affect disease activity and pain modulation in rheumatoid arthritis (RA) patients. Psychopharmacotherapy (PPT) of ADD attempts to improve RA disease activity and manage pain in RA patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22249f07831cc12535765fda70fa3811
https://doi.org/10.1136/annrheumdis-2022-eular.1103
https://doi.org/10.1136/annrheumdis-2022-eular.1103
Autor:
A. Borisova, T. Lisitsyna, D. Veltishchev, T. Reshetnyak, O. Seravina, O. Kovalevskaya, F. Cheldieva
Publikováno v:
Annals of the Rheumatic Diseases. 81:1373.1-1373
BackgroundSuicidal ideations in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) patients are associated with stress related depressive and anxiety disorders and can lead to higher mortality rates.ObjectivesTo describe the rates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d43348e647dccb03f05a3fb99fb53c00
https://doi.org/10.1136/annrheumdis-2022-eular.1956
https://doi.org/10.1136/annrheumdis-2022-eular.1956
Publikováno v:
Annals of the Rheumatic Diseases. 81:1750.2-1750
Backgroundclinical manifestations of Behcet’s Disease (BD) determine the prognosis and differ in patients of different ethnicity.Objectivesto describe the ethnicity related clinical features of Russian Federation’s cohort of BD patient’s.Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e31ef80b064a391dcfaade0e3756e379
https://doi.org/10.1136/annrheumdis-2022-eular.1737
https://doi.org/10.1136/annrheumdis-2022-eular.1737
Publikováno v:
Annals of the Rheumatic Diseases. 81:390.2-391
BackgroundOlokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients with moderate to severely active RA receiving OKZ or placeb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::459628a03d943ab1dd167fa4022a90dc
https://doi.org/10.1136/annrheumdis-2022-eular.1990
https://doi.org/10.1136/annrheumdis-2022-eular.1990
Publikováno v:
Annals of the Rheumatic Diseases. 81:1750.1-1750
BackgroundIn Behcet’s Disease (BD) some major organs are more involved in men and have worse outcomes. Gender related clinical features of BD are different in various countries.Objectivesto describe the gender related clinical features of Russian F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ee5cfa750ce615303331e7ec9f298b5
https://doi.org/10.1136/annrheumdis-2022-eular.1702
https://doi.org/10.1136/annrheumdis-2022-eular.1702
Publikováno v:
Annals of the Rheumatic Diseases. 81:1204.1-1204
BackgroundBehçet’s disease (BD) is a systemic variable vessel vasculitis with different clinical manifestations. BD does not have specific laboratory findings. Neutrophil hyperactivation is a major pathogenic factor in BD-related inflammation and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ebce88d95f2d420e7570d625a4b26bd
https://doi.org/10.1136/annrheumdis-2022-eular.1044
https://doi.org/10.1136/annrheumdis-2022-eular.1044
Publikováno v:
Bulletin of Experimental Biology and Medicine. 91:169-171
Ampicillin administration during pregnancy exerted no toxic effect on the developing fetus. However, it decreased the body weight of the progeny and the weight of the placenta. Oxacillin had an adverse effect on the pregnancy, labor, fetus and newbor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8334d244684ca0dccab4cc5afae7377
https://doi.org/10.1007/bf00835398
https://doi.org/10.1007/bf00835398
Publikováno v:
Bulletin of Experimental Biology and Medicine. 82:1076-1078
Penicillin, if injected into rats in large doses at different stages of pregnancy, had no adverse effect on the developing fetus or the newborn rat. Meanwhile benzathine penicillin (bicillin-3) caused resorption of the embryonic cells and acted adver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::695d2375a25a87edda55f94691845728
https://doi.org/10.1007/bf00789876
https://doi.org/10.1007/bf00789876